Histone Deacetylase Inhibitors Market Segmentation:
Route of Administration Segment Analysis
The oral HDAC inhibitors segment in the histone deacetylase inhibitors market is estimated to hold 55.0% of the revenue share over the assessed timeline. The worldwide availability and acceptability of orally administrated medications are the major driving factors in this segment. These epigenetic agents have several potential benefits, including the seamless regulation of gene expression, a broad spectrum of applications, and patient convenience. Furthermore, the segment’s proprietorship can be testified by the enlarging solid oral medicine industry, which attained a value of USD 550.0 million in 2022. Additionally, it was observed that 54.0% of the total new drug applications approved by the FDA from 1938 to 2022 had oral administration, as per NLM.
Application Segment Analysis
The histone deacetylase inhibitors market from the oncology segment is set to garner a notable share by the end of 2035. HDAC inhibitors (HDACis) hold a promising avenue in the field of oncology as ongoing research and clinical trials are continually exploring their effectiveness in treating different types of cancers. Moreover, as a novel class of anticancer therapeutic targets, this subtype is highly prioritized by international authorities and drug developers, presenting this medical discipline as a profitable segment. On this note, in November 2023, Acrotech Biopharma received clearance from the FDA for its Belinostat (BELEODAQ) relapsed or refractory peripheral T-cell lymphoma. Further, the Oncologic Drugs Advisory Committee suggested the FDA and Acrotech collaborate to work on mitigating approval delays in oncology.
Our in-depth analysis of the global histone deacetylase inhibitors market includes the following segments:
|
Classification |
|
|
Application |
|
|
Drugs |
|
|
End user |
|
|
Distribution Channel |
|
|
Route of Administration |
|
